Related references
Note: Only part of the references are listed.Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series
Paul T. Finger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAFV600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
Ernesto Rossi et al.
FRONTIERS IN ONCOLOGY (2019)
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Ernesto Rossi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J. Sullivan et al.
NATURE MEDICINE (2019)
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto et al.
NATURE MEDICINE (2019)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas et al.
NATURE MEDICINE (2019)
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Felicity Newel et al.
NATURE COMMUNICATIONS (2019)
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
Ernesto Rossi et al.
CANCERS (2019)
Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy
Natsuko Iga et al.
CANCER SCIENCE (2019)
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan et al.
EUROPEAN JOURNAL OF CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
J S Weber et al.
ANNALS OF ONCOLOGY (2019)
Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma
Ernesto Rossi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Markus Heppt et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A. Ascierto et al.
JAMA ONCOLOGY (2019)
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Ulrich Keilholz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
Meredith S. Pelster et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
Omid Hamid et al.
BRITISH JOURNAL OF CANCER (2018)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2018)
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S. Carlino et al.
EUROPEAN JOURNAL OF CANCER (2018)
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
Kenjiro Namikawa et al.
EUROPEAN JOURNAL OF CANCER (2018)
Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma
Oded Sagiv et al.
JAMA OPHTHALMOLOGY (2018)
Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma
Leandro J. Chaves et al.
OCULAR ONCOLOGY AND PATHOLOGY (2018)
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
Teresa M. Petrella et al.
EUROPEAN JOURNAL OF CANCER (2017)
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P. D'Angelo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
Corneel Coens et al.
LANCET ONCOLOGY (2017)
Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study
Giovanni Schinzari et al.
MELANOMA RESEARCH (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa
Joshua Ford et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2017)
Systematic genomic and translational efficiency studies of uveal melanoma
Chelsea Place Johnson et al.
PLOS ONE (2017)
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
Jinfeng Cao et al.
ONCOTARGET (2017)
Pembrolizumab for Recurrent Conjunctival Melanoma
Ashwini Kini et al.
JAMA OPHTHALMOLOGY (2017)
Molecular Characteristics of Conjunctival Melanoma Using Whole-Exome Sequencing
Swarup S. Swaminathan et al.
JAMA OPHTHALMOLOGY (2017)
Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma
Ester Simeone et al.
ONCOIMMUNOLOGY (2017)
Atezolizumab (A) plus cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.
Wilson H. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Systemic Treatment of Metastatic Conjunctival Melanoma
Simao Pinto Torres et al.
CASE REPORTS IN ONCOLOGICAL MEDICINE (2017)
Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma
Alexander N. Shoushtari et al.
CANCER (2016)
Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies
Alain P. Algazi et al.
CANCER (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
Ioannis Karydis et al.
ONCOIMMUNOLOGY (2016)
Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma
Walter J. Urba et al.
CANCER RESEARCH (2015)
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
Michele Maio et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review
Douglas B. Johnson et al.
ONCOLOGIST (2015)
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Aitziber Buque et al.
ONCOIMMUNOLOGY (2015)
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
A. M. Di Giacomo et al.
ANNALS OF ONCOLOGY (2015)
Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors
Allison Ackerman et al.
CANCER (2014)
The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis
Simon J. Furney et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
D. McDermott et al.
ANNALS OF ONCOLOGY (2013)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management
Michael A. Postow et al.
CURRENT ONCOLOGY REPORTS (2012)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
Ahmad Tarhini et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Andrea Boni et al.
CANCER RESEARCH (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas
Dan-Ning Hu et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Carol Beadling et al.
CLINICAL CANCER RESEARCH (2008)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Incidence of uveal melanoma in the United States: 1973-1997
AD Singh et al.
OPHTHALMOLOGY (2003)
Share Paper
